EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prophylactic Supplementation with Lactobacillus Reuteri or Its Metabolite GABA Protects Against Acute Ischemic Cardiac Injury

Jiawan Wang iD, Hao Zhang iD, Hailong Yuan iD, Siqi Chen iD, Ying Yu, Xuan Zhang, Zeyu Gao, Heng Du iD, Weitao Li, Yaohui Wang, Pengyan Xia, Jun Wang iD und 1 weitere

Advanced Science · 2024-05 · 11 (18)

DOI: 10.1002/advs.202307233 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 15.03.2024. Verfasst von Jiawan Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, 100101, China. Hauptthemen laut MEDLINE: Limosilactobacillus reuteri, gamma-Aminobutyric Acid, Mice, Inbred C57BL, Probiotics. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Program of the Beijing Natural Science Foundation, National Key Research and Development Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The gut microbiome has emerged as a potential target for the treatment of cardiovascular disease. Ischemia/reperfusion (I/R) after myocardial infarction is a serious complication and whether certain gut bacteria can serve as a treatment option remains unclear. Lactobacillus reuteri ( L. reuteri ) is a well‐studied probiotic that can colonize mammals including humans with known cholesterol‐lowering properties and anti‐inflammatory effects. Here, the prophylactic cardioprotective effects of L. reuteri or its metabolite γ‐aminobutyric acid (GABA) against acute ischemic cardiac injury caused by I/R surgery are demonstrated. The prophylactic gavage of L. reuteri or GABA confers cardioprotection mainly by suppressing cardiac inflammation upon I/R. Mechanistically, GABA gavage results in a decreased number of proinflammatory macrophages in I/R hearts and GABA gavage no longer confers any cardioprotection in I/R hearts upon the clearance of macrophages. In vitro studies with LPS‐stimulated bone marrow‐derived macrophages (BMDM) further reveal that GABA inhibits the polarization of macrophages toward the proinflammatory M1 phenotype by inhibiting lysosomal leakage and NLRP3 inflammasome activation. Together, this study demonstrates that the prophylactic oral administration of L. reuteri or its metabolite GABA attenuates macrophage‐mediated cardiac inflammation and therefore alleviates cardiac dysfunction after I/R, thus providing a new prophylactic strategy to mitigate acute ischemic cardiac injury.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Limosilactobacillus reuterigamma-Aminobutyric AcidMice, Inbred C57BLProbioticsDisease Models, AnimalAnimalsMiceMaleMyocardial Reperfusion InjuryMacrophagesGastrointestinal MicrobiomeMyocardial Ischemia

Stichwörter der Autor:innen

GABALactobacillus reuteriacute ischemic cardiac injurymicrobiota‐derived metaboliteprophylactic supplementation

Substanzen

gamma-Aminobutyric Acid

Autor:innen und Institutionen

  • State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, 100101, China.
  • Beijing Institute for Stem Cell and Regenerative Medicine, Beijing, 100101, China.
  • Key Laboratory of Organ Regeneration and Reconstruction, Chinese Academy of Sciences, Beijing, 100101, China.
  • Beijing Chao-Yang Hospital, Department of Anesthesiology, Beijing, 100020, China.
  • University of Chinese Academy of Sciences, Beijing, 100049, China.
  • Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng, 475004, China.

ORCID-Profile: Jiawan Wang, Hao Zhang, Hailong Yuan, Siqi Chen, Heng Du, Jun Wang, Moshi Song

Förderung

  • Program of the Beijing Natural Science Foundation
  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Young Scientists in Basic Research
  • State Key Laboratory of Membrane Biology
  • Laboratory of Organ Regeneration and Reconstruction, Chinese Academy of Sciences
  • Initiative Scientific Research Program, Institute of Zoology, Chinese Academy of Sciences

Zitieren

APA

Wang, J., Zhang, H., Yuan, H., Chen, S., Yu, Y., Zhang, X., Gao, Z., Du, H., Li, W., Wang, Y., Xia, P., Wang, J., & Song, M. (2024). Prophylactic Supplementation with Lactobacillus Reuteri or Its Metabolite GABA Protects Against Acute Ischemic Cardiac Injury. Advanced Science, 11(18). https://doi.org/10.1002/advs.202307233

Vancouver

Wang J, Zhang H, Yuan H, Chen S, Yu Y, Zhang X, et al. Prophylactic Supplementation with Lactobacillus Reuteri or Its Metabolite GABA Protects Against Acute Ischemic Cardiac Injury. Advanced Science. 2024;11(18). doi:10.1002/advs.202307233

BibTeX
@article{Wang2024,
  author = {Wang, Jiawan and Zhang, Hao and Yuan, Hailong and Chen, Siqi and Yu, Ying and Zhang, Xuan and Gao, Zeyu and Du, Heng and Li, Weitao and Wang, Yaohui and Xia, Pengyan and Wang, Jun and Song, Moshi},
  title = {Prophylactic Supplementation with Lactobacillus Reuteri or Its Metabolite GABA Protects Against Acute Ischemic Cardiac Injury},
  journal = {Advanced Science},
  year = {2024},
  volume = {11},
  number = {18},
  doi = {10.1002/advs.202307233}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche